

SIMPULAN

Pretomanid memiliki aktivitas bakterisid yang efektif pada dosis 200 mg/hari. Namun, efek samping sering terjadi, utamanya kenaikan enzim hati dan efek *gastrointestinal*. Selain itu, masih cukup sulit untuk menarik kesimpulan terkait potensi dalam memendekkan durasi pengobatan berdasarkan studi yang hanya dilakukan dalam 2 hingga 8.

SARAN

Diperlukan penelitian uji klinis dalam fase lebih lanjut untuk memperkaya data efektifitas dan keamanan pengobatan. Di samping itu, salah satu keterbatasan studi terkait pretomanid adalah tidak ditemukannya penelitian pada tempat yang cukup bervariasi (kebanyakan di Afrika Selatan) yang berpotensi membatasi generalisasi temuan serta populasi sampel yang cukup kecil.

DAFTAR PUSTAKA

- Zumla A, Raviglione M, Hafner R, von Reyn F. 2013. Tuberculosis. *N Engl J Med*; 368: 745–55.
- Zumla A, Gillespie SH, Hoelscher M, et al. 2014. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. *Lancet Infect Dis*; 14: 327–40.
- Bashiri, G., Squire, C.J., Moreland, N.J., Baker, E.N., 2008. Crystal structures of F420-dependent glucose-6-phosphate dehydrogenase FGD1 involved in the activation of the anti-tuberculosis drug candidate PA-824 reveal the basis of coenzyme and substrate binding. *J. Biol. Chem.* 283, 17531–17541. <https://doi.org/10.1074/jbc.M801854200>
- Chaudhari, H.K., Pahelkar, A., 2019. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine. *Infect Disord Drug Targets* 19, 145–166. <https://doi.org/10.2174/1871526518666181015145545>
- Choi, K.P., Bair, T.B., Bae, Y.M., Daniels, L., 2001. Use of transposon Tn5367 mutagenesis and a nitroimidazopyran-based selection system to demonstrate a requirement for fbiA and fbiB in coenzyme F(420) biosynthesis by *Mycobacterium bovis* BCG. *J. Bacteriol.* 183, 7058–7066. <https://doi.org/10.1128/JB.183.24.7058-7066.2001>
- Stover CK, Warrenner P, VanDevanter DR, et al. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. *Nature* 2000;405:962-6.
- Clain, J.M., Escalante, P., 2016. Novel Treatments for Drug-Resistant Tuberculosis. *Clinical Medicine Insights: Therapeutics* 8, CMT.S18560. <https://doi.org/10.4137/CMT.S18560>
- Conradie, F., Diacon, A.H., Ngubane, N., Howell, P., Everitt, D., Crook, A.M., Mendel, C.M., Egizi, E., Moreira, J., Timm, J., McHugh, T.D., Wills, G.H., Bateson, A., Hunt, R., Van Niekerk, C., Li, M., Olugbosi, M., Spigelman, M., 2020. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. *N Engl J Med* 382, 893–902. <https://doi.org/10.1056/NEJMoa1901814>

- Dawson, R., Diacon, A.H., Everitt, D., van Niekerk, C., Donald, P.R., Burger, D.A., Schall, R., Spigelman, M., Conradie, A., Eisenach, K., Venter, A., Ive, P., Page-Shipp, L., Variava, E., Reither, K., Ntinginya, N.E., Pym, A., von Groote-Bidlingmaier, F., Mendel, C.M., 2015. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. *The Lancet* 385, 1738–1747. [https://doi.org/10.1016/S0140-6736\(14\)62002-X](https://doi.org/10.1016/S0140-6736(14)62002-X)
- Diacon, Andreas H., Dawson, R., du Bois, J., Narunsky, K., Venter, A., Donald, P.R., van Niekerk, C., Erond, N., Ginsberg, A.M., Becker, P., Spigelman, M.K., 2012. Phase II Dose-Ranging Trial of the Early Bactericidal Activity of PA-824. *Antimicrob. Agents Chemother.* 56, 3027–3031. <https://doi.org/10.1128/AAC.06125-11>
- Diacon, A.H., Dawson, R., Hanekom, M., Narunsky, K., Maritz, S.J., Venter, A., Donald, P.R., van Niekerk, C., Whitney, K., Rouse, D.J., Laurenzi, M.W., Ginsberg, A.M., Spigelman, M.K., 2010. Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients. *AAC* 54, 3402–3407. <https://doi.org/10.1128/AAC.01354-09>
- Diacon, A.H., Dawson, R., von Groote-Bidlingmaier, F., Symons, G., Venter, A., Donald, P.R., van Niekerk, C., Everitt, D., Hutchings, J., Burger, D.A., Schall, R., Mendel, C.M., 2015. Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline. *Am J Respir Crit Care Med* 191, 943–953. <https://doi.org/10.1164/rccm.201410-1801OC>
- Diacon, Andreas H, Dawson, R., von Groote-Bidlingmaier, F., Symons, G., Venter, A., Donald, P.R., van Niekerk, C., Everitt, D., Winter, H., Becker, P., Mendel, C.M., Spigelman, M.K., 2012. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. *The Lancet* 380, 986–993. [https://doi.org/10.1016/S0140-6736\(12\)61080-0](https://doi.org/10.1016/S0140-6736(12)61080-0)
- FDA, 2019. US Food and Drug Administration. FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs. 14 Aug 2019. <https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs>.

- Migliori GB, et al, 2013. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. *Eur Respir J* 2013; 42: 169–79.
- Gotham, D., Fortunak, J., Pozniak, A., Khoo, S., Cooke, G., Nytko, F.E., Hill, A., 2017. Estimated generic prices for novel treatments for drug-resistant tuberculosis. *J. Antimicrob. Chemother.* 72, 1243–1252. <https://doi.org/10.1093/jac/dkw522>
- Jarrad, A.M., Ang, C.W., Debnath, A., Hahn, H.J., Woods, K., Tan, L., Sykes, M.L., Jones, A.J., Pelingon, R., Butler, M.S., Avery, V.M., West, N.P., Karoli, T., Blaskovich, M.A.T., Cooper, M.A., 2018. Design, Synthesis, and Biological Evaluation of 2-Nitroimidazopyrazin-one/-es with Antitubercular and Antiparasitic Activity. *J. Med. Chem.* 61, 11349–11371. <https://doi.org/10.1021/acs.jmedchem.8b01578>
- Kmietowicz, Z., 2012. New drug combination for TB is tested in unique trial. *BMJ* 345, e5060. <https://doi.org/10.1136/bmj.e5060>
- Li, X., Manjunatha, U.H., Goodwin, M.B., Knox, J.E., Lipinski, C.A., Keller, T.H., Barry, C.E., Dowd, C.S., 2008. Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824. *Bioorg. Med. Chem. Lett.* 18, 2256–2262. <https://doi.org/10.1016/j.bmcl.2008.03.011>
- Mohamed, A.E., Condic-Jurkic, K., Ahmed, F.H., Yuan, P., O'Mara, M.L., Jackson, C.J., Coote, M.L., 2016. Hydrophobic Shielding Drives Catalysis of Hydride Transfer in a Family of F420H2-Dependent Enzymes. *Biochemistry* 55, 6908–6918. <https://doi.org/10.1021/acs.biochem.6b00683>
- Momin, M.A.M., Thien, S.J., Krittaphol, W., Das, S.C., 2017. Simultaneous HPLC assay for pretomanid (PA-824), moxifloxacin and pyrazinamide in an inhaler formulation for drug-resistant tuberculosis. *J Pharm Biomed Anal* 135, 133–139. <https://doi.org/10.1016/j.jpba.2016.11.046>
- Mushtaq, A., 2019. Breakthrough in the treatment of drug-resistant tuberculosis. *Lancet Respir Med* 7, 1011. [https://doi.org/10.1016/S2213-2600\(19\)30376-5](https://doi.org/10.1016/S2213-2600(19)30376-5)
- Purwantini, E., Mukhopadhyay, B., 2013. Rv0132c of *Mycobacterium tuberculosis* encodes a coenzyme F420-dependent hydroxymycolic acid dehydrogenase. *PLoS ONE* 8, e81985. <https://doi.org/10.1371/journal.pone.0081985>

- Tyagi S, 2005. Tyagi S, Nuermberger E, Yoshimatsu T, et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. *Antimicrob Agents Chemother* 2005;49:2289-93.
- Tweed, C.D., Dawson, R., Burger, D.A., Conradie, A., Crook, A.M., Mendel, C.M., Conradie, F., Diacon, A.H., Ntinginya, N.E., Everitt, D.E., Haraka, F., Li, M., van Niekerk, C.H., Okwera, A., Rassool, M.S., Reither, K., Sebe, M.A., Staples, S., Variava, E., Spigelman, M., 2019. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. *The Lancet Respiratory Medicine* 7, 1048–1058. [https://doi.org/10.1016/S2213-2600\(19\)30366-2](https://doi.org/10.1016/S2213-2600(19)30366-2)
- Wallis, R.S., Jakubiec, W., Mitton-Fry, M., Ladutko, L., Campbell, S., Paige, D., Silvia, A., Miller, P.F., 2012. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. *PLoS ONE* 7, e30479. <https://doi.org/10.1371/journal.pone.0030479>
- WHO, 2014. The end TB strategy. Geneva: World Health Organization, 2014 (http://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1).
- WHO, n.d. Tuberculosis [WWW Document]. WHO. URL <https://www.who.int/westernpacific/health-topics/tuberculosis> (accessed 8.16.20).